TNB383B

TeneoOne is a clinical-stage biotechnology company that was specifically established as a subsidiary of Teneobio to facilitate the development of TNB-383B, now known as ABBV-383. The company's primary focus is the development of this bispecific antibody, which targets B-cell maturation antigen (BCMA) and CD3 to treat relapsed or refractory multiple myeloma. In 2021, AbbVie exercised its exclusive right to acquire TeneoOne following encouraging results from a Phase 1 study. The acquisition integrated TeneoOne's lead asset into AbbVie's oncology pipeline, where it is currently being evaluated in late-stage clinical trials. The therapy is designed to provide a potent and convenient treatment option for patients who have exhausted other lines of therapy.